Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + gefitinib
- Development stage
- Preclinical
- Lead developer
- Exelixis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of cabozantinib and gefitinib. Cabozantinib is a multi-target tyrosine kinase inhibitor that targets VEGFR-1, -2, -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2, while gefitinib is an EGFR tyrosine kinase inhibitor. This combination has shown synergistic effects in preclinical studies, particularly in crizotinib-resistant non-small cell lung cancer models with ROS1 fusion.
02
Targets
AXL (AXL receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)NTRK2 (Tropomyosin-related kinase receptor type B)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on cabozantinib + gefitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + gefitinib.